20 articles
24-week trial tested fucoxanthin-rich microalgae supplement on memory, attention, and executive function in 66 healthy seniors.
Small trial tested whether fish oil and alpha lipoic acid could slow Alzheimer's by reducing oxidative stress markers in blood.
A completed pilot trial tests whether 2g/day of a novel carnosine formulation can restore neuromuscular function and quality of life in MS patients.
A completed Phase 4 trial from India evaluates whether ALA supplementation boosts flunarizine's migraine-prevention power in adolescents.
A completed trial tests whether daily Nordic berry beverages can sharpen cognition in healthy adults over 12 weeks.
Italian researchers test plant-based compounds for brain health and quality of life in aging adults with promising early results.
A Phase 2 open-label trial explores whether an approved immune drug can raise frataxin protein levels and slow neurological decline in Friedreich Ataxia.
18-month trial tested omega-3 supplementation in 774 older adults with low DHA/EPA levels and memory concerns to prevent cognitive decline.
The EPICURO trial tests MERIVAยฎ turmeric over 6 months to see if it protects cognition in adults with metabolic syndrome.
A phase 2/3 trial of the BACE inhibitor atabecestat in amyloid-positive asymptomatic adults was terminated before completion, raising questions about this drug class.
A Phase 4 RCT tests whether one bevacizumab injection matches two combined doses for neovascular AMD outcomes over 12 months.
A completed Phase 1 trial compared the abuse liability of rapastinel versus ketamine in recreational polydrug users, with implications for safer depression treatment.
A Phase 4 real-world study comparing extended-release methylphenidate formulations for ADHD was terminated before yielding conclusions.
Probucol, a discontinued cholesterol medication, may boost brain-protective proteins in older adults at risk for dementia.
A completed trial tests EGCG combined with diet, exercise, and cognitive training to slow decline in ApoE4 carriers with early warning signs.
A completed Phase 1/2 pilot trial tested whether the senolytic duo D+Q penetrates the brain in early Alzheimer's disease.
A Phase 2 trial investigates whether thiethylperazine, a decades-old antiemetic, can flush toxic amyloid beta from the brains of early AD patients.
A Phase 1/2 trial tests whether dexmedetomidine can enhance the brain's glymphatic system to clear amyloid and tau during sleep.
UC San Diego researchers tested psilocybin's safety and potential benefits for eating disorder symptoms in 16 participants with anorexia nervosa.
A Phase 1 trial of AV-1959R, an Aฮฒ-targeting vaccine, tests safety and antibody generation in healthy adults aged 40โ60.
